TriSalus Life Sciences, Inc.
For the period ended Jun 30, 2025. Filed Aug 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 12, 2025
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Deficit
Six months ended June 30, 2025 and 2024
(unaudited, in thousands except share data)
| Six months ended June 30, 2025 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Preferred stock · Common stock · Additional paid-in capital · Accumulated deficit · Total | |||||||||||||||||
| Shares · Amount · Shares · Amount | |||||||||||||||||
| At December 31, 2024 | 3,985,002 | $— | 31,279,264 | $3 | $253,652 | $(279,549) | $(25,894) | ||||||||||
| Exercise of options | — | — | 215,369 | — | 279 | — | 279 | ||||||||||
| Stock-based compensation | — | — | — | — | 1,620 | — | 1,620 | ||||||||||
| Preferred stock conversion | (365,000) | — | 777,829 | — | — | — | — | ||||||||||
| Net loss | — | — | — | — | — | (10,375) | (10,375) | ||||||||||
| At March 31, 2025 | 3,620,002 | — | 32,272,462 | $3 | $255,551 | $(289,924) | $(34,370) | ||||||||||
| Exercise of options | — | — | 155,051 | — | 56 | — | 56 | ||||||||||
| Stock-based compensation | — | — | — | — | 2,517 | (1) | — | 2,517 | |||||||||
| Proceeds from sale of common stock | — | — | 5,500,000 | — | 20,662 | — | 20,662 | ||||||||||
| Preferred stock conversion | (26,000) | — | 55,746 | — | — | — | — | ||||||||||
| Net loss | — | — | — | — | — | (8,288) | (8,288) | ||||||||||
| At June 30, 2025 | 3,594,002 | $— | 37,983,259 | $3 | $278,786 | $(298,212) | $(19,423) | ||||||||||
| (1) Amount reflects $0.6 million related to 2024 bonus paid in 2025 in the form of stock-based compensation. | |||||||||||||||||
| Six months ended June 30, 2024 | |||||||||||||||||
| Preferred stock · Common stock · Additional paid-in capital · Accumulated deficit · Total | |||||||||||||||||
| Shares · Amount · Shares · Amount | |||||||||||||||||
| At December 31, 2023 | 4,015,002 | $— | 26,413,213 | $2 | $222,437 | $(249,504) | $(27,065) | ||||||||||
| Exercise of options | — | — | (4,941) | (2) | — | 7 | — | $7 | |||||||||
| Stock-based compensation | — | — | — | — | 1,086 | — | $1,086 | ||||||||||
| Proceeds from sale of common stock | — | — | 350,000 | — | 3,141 | — | $3,141 | ||||||||||
| Net loss | — | — | — | — | — | (13,206) | (13,206) | ||||||||||
| At March 31, 2024 | 4,015,002 | — | 26,758,272 | $2 | $226,671 | $(262,710) | $(36,037) | ||||||||||
| Exercise of options | — | $— | 1,191 | — | 5 | — | 5 | ||||||||||
| Stock-based compensation | — | — | — | — | 1,275 | — | 1,275 | ||||||||||
| Proceeds from sale of common stock | — | — | 400,000 | — | 3,602 | — | 3,602 | ||||||||||
| Record exchange warrants | — | — | — | — | 11,923 | — | 11,923 | ||||||||||
| Record issuance costs | — | — | — | — | (1,699) | — | (1,699) | ||||||||||
| Net loss | — | — | — | — | — | (4,332) | (4,332) | ||||||||||
| At June 30, 2024 | 4,015,002 | $— | 27,159,463 | $2 | $241,777 | $(267,042) | $(25,263) | ||||||||||
(2)Amount reflects 2,906 shares issued for option exercises and 7,847 shares returned from options exercised in 2023 to correct clerical error.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.